HRMY Earnings & Financial Statements
Harmony Biosciences Holdings, Inc.
$38.27
+$0.76(+2.03%)
71
Overall
80
Value
70
Tech
63
Quality
Market Cap
$2.18B
Volume
791.18K
52W Range
$25.52 - $43.49
Target Price
$46.54
HRMY earnings and financial statements: Harmony Biosciences Holdings, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
HRMY Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $868.45M | $714.73M | $582.02M | $437.86M | $305.44M |
| Cost of revenue | $198.34M | $156.81M | $121.24M | $83.48M | $55.52M |
| Operating income | $208.47M | $190.83M | $192.03M | $120.19M | $87.53M |
| EBITDA | $253.56M | $233.15M | $221.51M | $123.48M | $80.46M |
| Net income | $158.69M | $145.49M | $128.85M | $181.47M | $34.60M |
| EPS (diluted) | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.27B | $999.20M | $811.45M | $673.87M | $433.44M |
| Total liabilities | $401.41M | $340.05M | $344.46M | $271.03M | $246.94M |
| Shareholders’ equity | $870.22M | $659.15M | $466.99M | $402.84M | $186.51M |
| Cash and equivalents | $752.50M | $453.00M | $311.66M | $243.78M | $234.31M |
| Long-term debt | $143.66M | $163.02M | $178.57M | $189.65M | $189.98M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $348.20M | $219.82M | $219.39M | $144.47M | $98.56M |
| Capital expenditure | -$310.0K | -$1.15M | -$312.0K | -$172.0K | -$100.30M |
| Free cash flow | $347.89M | $218.67M | $219.07M | $144.29M | -$1.74M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | HRMY | $38.27 | +2.0% | 791.18K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Harmony Biosciences Holdings, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW